These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3027271)

  • 1. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
    Williams SF; Bitran JD; Kaminer L; Westbrook C; Jacobs R; Ashenhurst J; Robin E; Purl S; Beschorner J; Schroeder C
    J Clin Oncol; 1987 Feb; 5(2):260-5. PubMed ID: 3027271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer.
    Williams SF; Bitran JD; Hoffman PC; Robin E; Fullem L; Beschorner J; Golick J; Golomb HM
    Cancer; 1989 Jan; 63(2):238-42. PubMed ID: 2535952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
    Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
    J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
    Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
    J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
    Papadakis V; Dunkel IJ; Cramer LD; Kramer E; Papadopoulos E; Goldman S; Packer RJ; Willoughby M; Baker D; Garvin J; Strandjord S; Coccia P; Kaplan AM; Klemperer M; Finlay JL
    Bone Marrow Transplant; 2000 Jul; 26(2):153-60. PubMed ID: 10918425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.
    Kennedy MJ; Beveridge RA; Rowley SD; Gordon GB; Abeloff MD; Davidson NE
    J Natl Cancer Inst; 1991 Jul; 83(13):920-6. PubMed ID: 1906111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
    Kennedy MJ; Armstrong DK; Huelskamp AM; Ohly K; Clarke BV; Colvin OM; Grochow LB; Chen TL; Davidson NE
    J Clin Oncol; 1995 May; 13(5):1136-43. PubMed ID: 7738619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
    Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
    J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant.
    Myers SE; Mick R; Williams SF
    Bone Marrow Transplant; 1994 Apr; 13(4):449-54. PubMed ID: 8019470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
    Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN
    Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
    J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors.
    Eder JP; Antman K; Elias A; Shea TC; Teicher B; Henner WD; Schryber SM; Holden S; Finberg R; Chritchlow J
    J Natl Cancer Inst; 1988 Oct; 80(15):1221-6. PubMed ID: 3138431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
    J Clin Oncol; 1990 Nov; 8(11):1782-8. PubMed ID: 2121909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose thiotepa alone and in combination regimens with bone marrow support.
    Antman K; Eder JP; Elias A; Ayash L; Shea TC; Weissman L; Critchlow J; Schryber SM; Begg C; Teicher BA
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):33-8. PubMed ID: 2106166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.